uniQure (NASDAQ:QURE) Shares Down 4.8% – What’s Next?

uniQure (NASDAQ:QURE) shares were down 4.8% during trading on Tuesday . The company traded as low as $15.08 and last traded at $15.05. Approximately 74,702 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 1,144,552 shares. The stock had previously closed at $15.80.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. Guggenheim restated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Cantor Fitzgerald upped their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. HC Wainwright boosted their price target on shares of uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a report on Monday. The Goldman Sachs Group boosted their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Trading Down 0.2 %

The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The business’s 50 day simple moving average is $13.31 and its 200 day simple moving average is $8.84. The stock has a market cap of $741.19 million, a P/E ratio of -3.08 and a beta of 0.41.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. On average, analysts expect that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. abrdn plc increased its position in shares of uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. bought a new position in uniQure in the third quarter worth $7,360,000. Point72 Asset Management L.P. boosted its position in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares in the last quarter. FMR LLC lifted its stake in shares of uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after buying an additional 346,274 shares in the last quarter. Finally, Privium Fund Management B.V. boosted its position in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 104,500 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.